The XB Bio-Integration Suite represents a complete analytical and data management solution for health sciences researchers and clinicians with several key capabilities:
Integrate All Data
Integrated Research Platform
Utilizing XB Bio-Integration Suite™, researchers are able to access multi-variant
data sources (both internal to the organization and external public data stores),
create unique patient cohorts, analyze the data utilizing a broad spectrum of
analytic and statistical tools, and create unique, testable hypotheses. A spoke-level data mart is developed for the researcher, where he is able to integrate his
data with the organization's hub data warehouse, creating a data mart unique to
his study. After the completion of the study, the information the researcher
gathered from the primary care providers as well as the ultrasound images is
then merged back into the hub with appropriate enterprise data standards and
metadata, where it can be leveraged by other researchers looking for similar
information. The data is managed by the appropriate security services so that it
is only utilized for the use cases approved by the IRB, even when brought into
Personalized Medicine Module
TMS offers a Personalized Medicine Module (PMM) as a component-off-the-shelf
(COTS) add-on to XB-BIS. PMM leverages XB-BIS to generate a personalized
medicine report, which identifies molecularly targeted therapies based upon the
unique molecular profile of a patient's cancer. The report correlates molecular
characteristics of the patient's disease with potential drug therapies. The module
leverages multiple algorithms and the results are merged and ranked for the
oncologist's consideration. Following are the steps for producing a personalized
- Physician consults with an eligible patient and presents the personalized medicine report as an option.
- The physician's office collects key data on the patient's specific disease.
- Patient undergoes a tumor procedure as part of standard-of-care pathology practices to acquire a fresh tumor sample.
- A small portion of the tumor sample is sent to a designated CLIA lab for analysis.
- The lab processes the sample to develop a complete genomic signature of the patient's unique cancer.
- XB-BIS processes the gene expression data and analyzes the patient's information using a series of algorithms to identify key drug targets or signatures of drug response/resistance.
- The patient's unique profile is then interrogated against molecularly targeted drug databases to align molecular characteristics of the patient's disease with potential therapeutic interventions.
- XB-BIS invokes the MedTrust® oncology information service to search for related scientific and clinical evidence (publications, trials and research).
- XB-BIS generates the Personalized Medicine Report and delivers it to the physician through a secure website.
- Physician reviews the report to assist in developing an informed treatment plan with the patient.
Self-Service Cohort Identification
One of XB-BIS' main strengths is its ease of use. Researchers and clinicians are
not required to learn SQL or other programming languages in order to perform
complex queries and basic analysis. XB-BIS provides a simple and intuitive user
experience for querying and viewing data. TMS presents XB-BIS' cohort
identification features in a series of vignettes—starting simple and progressively
becoming more complex. Imagine a researcher interested in identifying and
evaluating mesothelioma patients and the detection of tumor markers at various
stages based upon age of patient, race and ethnicity. The researcher can
quickly and easily utilize the self-service cohort identification application to
identify the number of consented patients and tumors in the biorepository, and
then further refine the analysis set based on queried phenotype and molecular
data across all time. Utilizing the cohort identification application, sequence and
relative duration between events (key input to identifying members of the cohort)
are easily provided to the researcher.